Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion
- 15 March 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (6) , 2531-2535
- https://doi.org/10.1182/blood-2005-04-1768
Abstract
In multiple myeloma (MM), circulating endothelial cells (CECs) represent a vascular marker of angiogenesis and may reflect tumor mass. In this report, we showed that, in 5 MM patients with 13q14 deletion, CECs carried the same chromosome aberration as the neoplastic plasma cells (11%-32% of CECs with 13q14 deletion). Most of the CECs displayed immunophenotypic features of endothelial progenitor cells as they expressed CD133, a marker gradually lost during endothelial differentiation and absent on mature endothelial cells. To the contrary, in 3 patients with monoclonal gammopathy of undetermined significance and 13q14 deletion, CECs were cytogenetically normal and had a mature immunophenotype. In MM CECs, immunoglobulin genes were clonally rearranged. These findings suggest a possible origin of CECs from a common hemangioblast precursor that can give rise to both plasma cells and endothelial cells and point to a direct contribution of MM-derived CECs to tumor vasculogenesis and possibly to the spreading and progression of the disease. (Blood. 2006;107:2531-2535)Keywords
This publication has 20 references indexed in Scilit:
- Circulating endothelial progenitor cells in multiple myeloma: implications and significanceBlood, 2005
- Contribution of bone marrow–derived endothelial cells to human tumor vasculatureNature Medicine, 2005
- CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancerJournal of Clinical Pathology, 2004
- Advances in biology of multiple myeloma: clinical applicationsBlood, 2004
- Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell LymphomasNew England Journal of Medicine, 2004
- Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patientsAnnals of Oncology, 2004
- Vasculogenic mimicry and tumour-cell plasticity: lessons from melanomaNature Reviews Cancer, 2003
- Soluble urokinase‐type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra‐bone marrow involvement in multiple myeloma patientsBritish Journal of Haematology, 2003
- Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growthNature Medicine, 2001
- Mechanisms of angiogenesis and arteriogenesisNature Medicine, 2000